Literature DB >> 10973867

Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.

R Bergés1, J Segura, R Ventura, K D Fitch, A R Morton, M Farré, M Mas, X de La Torre.   

Abstract

BACKGROUND: The administration of salbutamol is permitted only by inhalation by the International Olympic Committee (IOC) for the management of asthma and exercise-induced asthma in athletes. The establishment of criteria to distinguish between the (IOC) authorized use (inhaled) and the (IOC) prohibited use (oral) of salbutamol appeared possible using simultaneous evaluation of variables based on the concentration of nonconjugated enantiomers of salbutamol excreted in urine.
METHODS: Urine was collected from asthmatic and nonasthmatic swimmers who had received various preexercise doses of oral (five doses of 4 mg) or inhaled (two doses of 100 microgram) salbutamol. Urine was also obtained from subjects who had received the maximum dosage of inhaled salbutamol advisable for competing athletes to provide protection from exercise-induced asthma and treatment of asthma (1600 microgram in 24 h, 800 microgram being in the last 4 h). All samples were analyzed to determine the total amount of unchanged salbutamol excreted in urine and the ratio between the S: and R: enantiomers.
RESULTS: The discriminant function D = -3.776 + 1.46 x 10(-3) ([S:(+)] + [R:(-)]) + 1.012 ([S:(+)]/[R(-)]) can be used to classify data into two groups, inhaled and oral. The confirmatory criterion suggested (cutoff at D = 1.06, 4 SD from the mean D value of the inhaled distribution) has been verified in different sets of samples showing suspicious concentrations by conventional screening procedures in doping control. An 11.8% false-negative (oral classified as inhaled) rate is assumed with the confirmatory criterion proposed, but virtually no false positives (inhaled classified as oral) are obtained (<1 in 33 000).
CONCLUSIONS: The overall procedure recommended is to screen all samples and to apply the confirmation criterion proposed to samples showing free racemic salbutamol concentrations >500 microgram/L by gas chromatography-mass spectrometry or free + conjugated racemic salbutamol concentrations >1400 microgram/L by ELISA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973867

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

Review 1.  The World Anti-Doping Code in sport: Update for 2015.

Authors:  David Hughes
Journal:  Aust Prescr       Date:  2015-10-01

2.  Beta2-Agonist Doping Control and Optical Isomer Challenges.

Authors:  Glenn A Jacobson; J Paul Fawcett
Journal:  Sports Med       Date:  2016-12       Impact factor: 11.136

Review 3.  beta2-Agonists at the Olympic Games.

Authors:  Kenneth D Fitch
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 4.  The World Anti-Doping Code: can you have asthma and still be an elite athlete?

Authors:  Ken Fitch
Journal:  Breathe (Sheff)       Date:  2016-06

5.  Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.

Authors:  Perrine Courlet; Thierry Buclin; Jérôme Biollaz; Irene Mazzoni; Olivier Rabin; Monia Guidi
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-03-22

6.  Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.

Authors:  Fabien Pillard; Michel Lavit; Valérie Lauwers Cances; Jacques Rami; Georges Houin; Alain Didier; Daniel Rivière
Journal:  Respir Res       Date:  2015-12-24

7.  Futility of current urine salbutamol doping control.

Authors:  Jules A A C Heuberger; Sven C van Dijkman; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.